The MarketWatch News Department was not involved in the creation of this content. bioAffinity Technologies' noninvasive diagnostic shifted the course of care from watchful waiting for up to 5 years to ...

bioAffinity Technologies’ noninvasive diagnostic shifted the course of care from watchful waiting for up to 5 years to confirmed malignancy and immediate treatment SAN ANTONIO, September 09, ...

Introduction: Hook-wire (HW) localization is the most frequently employed approach for preoperative localization of pulmonary ground-glass nodules (GGNs); however, the relative outcomes of ...

bioAffinity Technologies’ noninvasive diagnostic shifted the course of care from watchful waiting for up to 5 years to confirmed malignancy and immediate treatment Ground-glass nodules appear in ...

In a 2024 Journal of Thoracic Oncology review, Haiquan Chen, MD, PhD, of Fudan University Shanghai Cancer Center in China, and colleagues backed the use of selective lymph node dissection (LND) to ...

Precision medicine, genetics and genomics in a community cancer clinic. This is an ASCO Meeting Abstract from the 2020 ASCO Annual Meeting I. This abstract does not include a full text component.

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today released another compelling case study in ...

bioAffinity Technologies’ noninvasive diagnostic shifted the course of care from watchful waiting for up to 5 years to confirmed malignancy and immediate treatment SAN ANTONIO--(BUSINESS WIRE)-- ...

bioAffinity Technologies’ noninvasive diagnostic shifted the course of care from watchful waiting for up to 5 years to confirmed malignancy and immediate treatment SAN ANTONIO--(BUSINESS WIRE)--#BIAF- ...

Genomic profiling of breast cancer in African American women. TP53-mutation status by gene-expression signature (TP53 signature) and prediction of efficacy of neoadjuvant chemotherapy (NAC) and ...